Smital Shah
Director/Board Member en PLIANT THERAPEUTICS, INC. .
Fortuna: 18 757 $ al 31/03/2024
Perfil
Smital Shah is an Independent Director at Pliant Therapeutics, Inc. She previously served as an Independent Director at Graphite Bio, Inc. and as Treasurer at Gilead Sciences, Inc. from 2012 to 2014.
From 2018 to 2022, she held the position of Chief Financial & Business Officer at ProQR Therapeutics NV.
Ms. Shah holds an MBA from the University of California, Berkeley and the Haas School of Business.
She also has a graduate degree from Virginia Polytechnic Institute & State University and an undergraduate degree from the University of Mumbai.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0.00% | 01/02/2024 | 840 ( 0.00% ) | 18 757 $ | 31/03/2024 |
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Smital Shah
| Empresas | Cargo | Inicio |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 14/03/2019 |
Antiguos cargos conocidos de Smital Shah.
| Empresas | Cargo | Fin |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Director of Finance/CFO | 01/10/2022 |
| GILEAD SCIENCES, INC. | Treasurer | 01/09/2014 |
| LENZ THERAPEUTICS, INC. | Director/Board Member | - |
Formación de Smital Shah.
| Virginia Polytechnic Institute & State University | Graduate Degree |
| University of Mumbai | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Smital Shah
